Recall due to increased release of active ingredient

On Friday 18.8.2023 a delegation of the Chinese Drug Administration Zhejiang Medical Products Administration visited the AGES Medical Market Surveillance for an exchange and deeper insights into the fields of activity.

Recall due to slightly increased peroxide number

Up-to-date information from the 17.07.-20.07.2023 meeting on new approvals, extensions of indication, newly published EPARs and recently started procedures.

10 years after the review of iron-containing drugs for intravenous use associated with allergic reactions, cautions are recalled.

The BASG warns against potency enhancers seized in Austria that contain undeclared synthetic active pharmaceutical ingredients, such as sildenafil or tadalafil.

The BASG warns against the product "TKTX Tattoo-Creme" because it has been classified as an illegal medicinal product by function.

Recall due to insufficient active substance release

les (vorzugsweise INN) / Name of the active pharmaceutical ingredient (preferably INN) |_| Neue Substanz / New substance bei im EWR neuen Wirkstoffen ("new active substances"), sowie/and Biosimilars) |_| [...] |_| Bekannte Substanz / Known substance bei im EWR bekannten Wirkstoffen ("existing active substances" mit der Ausnahme von/with the exception of Biosimilars) 2. Antragsteller / Applicant Name / Name Adresse [...] medicinal product Bezeichnung des arzneilich wirksamen Bestandteiles (vorzugsweise INN) / Name of the active pharmaceutical ingredient (preferably INN) (Geplante) therapeutische Indikation / (Planned) therapeutic

Referenced at:

• Scientific advice by BASG

Recall due to insufficient active substance release